首页 > 市场调查报告书 > 医疗设备

心血管设备

市场调查报告书

商品编码

1740965

结构性心臟设备市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Structural Heart Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年04月25日 | 出版商:

Global Market Insights Inc. | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2024年，全球结构性心臟器材市场规模达123亿美元，预计到2034年将以8.8%的复合年增长率成长，达到288亿美元。心血管疾病发病率的上升、医疗服务可近性的扩大以及微创治疗技术的广泛应用，共同推动了这一持续成长。随着全球老化人口的增加，高血压和糖尿病等慢性疾病日益普遍，直接导致结构性心臟疾病患者数量不断增加。尤其是瓣膜相关问题、先天性心臟缺陷以及影响心臟结构的疾病，其发生率不断上升，加剧了对先进治疗方案的需求。此外，认知度的提高、早期诊断和技术的进步，也显着改变了心血管领域的患者护理。

2023年，全球市场规模达113亿美元，呈现上升趋势。在所有产品类型中，心臟瓣膜装置在2024年创造了最高的收入，价值51亿美元。这一增长可归因于现代耐用型装置的日益普及，这些装置旨在恢復正常的心臟瓣膜功能，同时最大限度地减少开胸手术的需求。其他主要产品领域包括瓣环成形环、封堵器和输送系统，以及各种支援结构性介入的辅助技术。随着创新不断提升这些工具的安全性和有效性，临床医生拥有更多选择，可以根据患者的个人需求量身定制治疗方案。

市场范围
起始年份	2024
预测年份	2025-2034
起始值	123亿美元
预测值	288亿美元
复合年增长率	8.8%

结构性心臟病，例如心肌病变和瓣膜疾病，需要立即有效的治疗，因此人们高度重视设备性能和手术技巧的技术改进。微创方法的发展带来了变革性的影响，尤其是在经导管瓣膜置换术等手术中，它缩短了患者的恢復时间和住院时间。随着这些方法的日益精进，患者的预后正在改善，併发症也在减少，推动了医疗体系的广泛采用。尖端材料、即时成像功能以及更符合人体工学的设计的融合也提高了医生在复杂干预过程中的准确性，从而实现了更好的治疗效果。

从手术角度来看，市场细分为修復手术和置换手术。 2024年，置换手术占据了该细分市场的主导地位，收入超过73亿美元。非手术和机器人辅助技术的不断进步，提高了手术的精准度并降低了手术风险，促使人们对置换手术日益青睐。这些改进推动了治疗模式的转变，转向专注于长期疗效和改善患者生活品质的疗法。置换手术也受益于临床研究和真实世界资料，这些研究和数据验证了其有效性，从而鼓励医疗保健提供者更广泛地应用。

从终端用途来看，医院在2024年成为结构性心臟器械的最大消费者，预计到预测期末将产生52亿美元的市场规模。医院拥有技术精湛的医护人员、现代化的心臟科室和诊断能力，能够处理大量的心血管手术。随着结构性心臟治疗的日益复杂，医院在使用最先进的工具和系统提供全面护理方面继续发挥核心作用。它们也是转诊和术后护理的主要中心，进一步巩固了其在市场中的地位。

2024年，美国市场收入达38亿美元，预计2025年至2034年期间的复合年增长率将达到7.7%。美国市场主导地位主要得益于其先进的医疗基础设施、对新型医疗技术的早期应用以及结构性干预措施的优惠报销政策。心臟瓣膜疾病病例的增多，尤其是在老年人群中，正在推动对微创瓣膜置换疗法的需求。此外，主要市场参与者的强劲表现以及设备设计和手术流程的持续创新，将继续推动美国市场的成长。

全球结构性心臟器材市场竞争激烈，五大公司占约 75% 的市场。这些领先公司持续投入研发，以提升产品性能并简化复杂的干预措施。从增强即时视觉化到简化手术工作流程，製造商致力于为医生提供直觉、高效且对患者友好的解决方案，从而优化治疗效果并提高临床生产力。

产业生态系统分析
产业衝击力
- 成长动力
  - 心血管疾病负担日益加重
  - 技术进步
  - 有利的报销方案
  - 微创手术日益受到青睐
- 产业陷阱与挑战
  - 严格的监理政策
  - 潜在併发症和不良事件
成长潜力分析
监管格局
川普政府关税
- 对贸易的影响
  - 贸易量中断
  - 报復措施
- 对产业的影响
  - 供给侧影响（原料）
    - 主要材料价格波动
    - 供应链重组
    - 生产成本影响
  - 需求面影响（售价）
    - 价格传导至终端市场
    - 市占率动态
    - 消费者反应模式
- 受影响的主要公司
- 策略产业反应
  - 供应链重组
  - 定价和产品策略
  - 政策参与
- 展望与未来考虑
报销场景
2024年定价分析
技术格局
未来市场趋势
波特的分析
差距分析
PESTEL分析

第四章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
公司市占率分析
竞争定位矩阵
策略仪表板

第五章：市场估计与预测：按产品，2021 - 2034 年

主要趋势
心臟瓣膜装置
- 外科心臟瓣膜
- 经导管心臟瓣膜
瓣环成形环
封堵器和输送系统
其他产品

第六章：市场估计与预测：按程序，2021 - 2034 年

主要趋势
更换程序
- 外科主动脉瓣置换术（SAVR）
- 经导管主动脉瓣置换术（TAVR）
- 经导管二尖瓣置换术（TMVR）
- 其他更换程序
修復程式
- 左心耳封堵术（LAAC）
- 经导管二尖瓣修復术（TMVr）
- 经导管三尖瓣修復术（TTVr）
- 瓣膜成形术
- 其他修復程式

第七章：市场估计与预测：依最终用途，2021 - 2034 年

主要趋势
医院
门诊手术中心
心导管实验室
其他最终用途

第八章：市场估计与预测：按地区，2021 - 2034 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第九章：公司简介

Abbott
AtriCure
BIOMERICS
Boston Scientific
BRAILE
CryoLife
Edwards
JENAVALVE
LEPU MEDICAL
LivaNova
Medtronic
NUMED

简介目录

Product Code: 3231

The Global Structural Heart Devices Market was valued at USD 12.3 billion in 2024 and is estimated to grow at a CAGR of 8.8% to reach USD 28.8 billion by 2034. This consistent growth is fueled by the increasing incidence of cardiovascular diseases, expanding access to healthcare services, and the widespread adoption of minimally invasive treatment techniques. As aging populations rise globally, chronic health conditions such as hypertension and diabetes become more prevalent, directly contributing to the increasing number of patients diagnosed with structural heart disorders. In particular, valve-related issues, congenital heart defects, and conditions impacting the heart's structure are becoming more frequent, intensifying the demand for advanced treatment solutions. Moreover, greater awareness, early diagnosis, and technological advances have significantly transformed patient care in the cardiovascular segment.

In 2023, the global market stood at USD 11.3 billion, reflecting its upward trajectory. Among the product types, heart valve devices generated the highest revenue in 2024, valued at USD 5.1 billion. This growth can be attributed to the increasing use of modern, durable devices designed to restore proper heart valve function while minimizing the need for open-heart surgery. Other key product segments include annuloplasty rings, occluders, and delivery systems, along with various supportive technologies that enable structural interventions. As innovation continues to enhance the safety and effectiveness of these tools, clinicians have more options for customizing treatment to individual patient needs.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$12.3 Billion
Forecast Value	$28.8 Billion
CAGR	8.8%

Structural heart conditions such as cardiomyopathies and valve diseases demand immediate and efficient management, which has led to a strong emphasis on technological enhancements in device performance and procedural techniques. The development of minimally invasive approaches has had a transformative effect, especially with procedures such as transcatheter valve replacements that reduce recovery time and hospital stays. As these methods become more refined, patient outcomes are improving and complications are decreasing, driving greater adoption across healthcare systems. The integration of cutting-edge materials, real-time imaging capabilities, and more ergonomic designs have also elevated physician accuracy during complex interventions, allowing for better therapeutic results.

From a procedural standpoint, the market is segmented into repair and replacement procedures. Replacement procedures dominated the segment in 2024, accounting for more than USD 7.3 billion in revenue. The increasing preference for replacement methods stems from ongoing advances in non-surgical and robotic-assisted techniques that offer enhanced precision and reduced procedural risks. These improvements have supported a shift in treatment paradigms toward therapies that prioritize long-term durability and improved quality of life for patients. Replacement procedures also benefit from clinical studies and real-world data that validate their effectiveness, encouraging broader use among healthcare providers.

In terms of end use, hospitals emerged as the largest consumers of structural heart devices in 2024 and are projected to generate USD 5.2 billion by the end of the forecast period. Hospitals are well-equipped with skilled personnel, modern cardiac units, and diagnostic capabilities, enabling them to handle high volumes of cardiovascular procedures. With the increasing complexity of structural heart treatments, hospitals continue to play a central role in delivering comprehensive care using state-of-the-art tools and systems. They are also the primary hubs for referrals and post-surgical care, further strengthening their position in the market.

The United States accounted for USD 3.8 billion in market revenue in 2024 and is expected to grow at a CAGR of 7.7% between 2025 and 2034. The country's dominance is largely supported by its advanced healthcare infrastructure, early adoption of novel medical technologies, and favorable reimbursement policies for structural interventions. Rising cases of heart valve disorders, especially among older adults, are increasing the demand for less invasive valve replacement therapies. Additionally, the strong presence of key market players and ongoing innovation in device design and procedural workflows continue to drive market growth across the country.

The global structural heart devices market is characterized by high competition, with five major companies holding approximately 75% of the total market share. These leading firms are continuously investing in research and development to improve product performance and simplify complex interventions. From enhancing real-time visualization to streamlining surgical workflows, manufacturers are focused on supporting physicians with intuitive, efficient, and patient-friendly solutions that optimize outcomes and boost clinical productivity.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing burden of cardiovascular diseases
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Favorable reimbursement scenario
  - 3.2.1.4 Rising preference for minimally invasive procedures
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulatory policies
  - 3.2.2.2 Potential complications and adverse events
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Trump administration tariffs
- 3.5.1 Impact on trade
  - 3.5.1.1 Trade volume disruptions
  - 3.5.1.2 Retaliatory measures
- 3.5.2 Impact on the Industry
  - 3.5.2.1 Supply-side impact (raw materials)
    - 3.5.2.1.1 Price volatility in key materials
    - 3.5.2.1.2 Supply chain restructuring
    - 3.5.2.1.3 Production cost implications
  - 3.5.2.2 Demand-side impact (selling price)
    - 3.5.2.2.1 Price transmission to end markets
    - 3.5.2.2.2 Market share dynamics
    - 3.5.2.2.3 Consumer response patterns
- 3.5.3 Key companies impacted
- 3.5.4 Strategic industry responses
  - 3.5.4.1 Supply chain reconfiguration
  - 3.5.4.2 Pricing and product strategies
  - 3.5.4.3 Policy engagement
- 3.5.5 Outlook and future considerations
3.6 Reimbursement scenario
3.7 Pricing analysis, 2024
3.8 Technology landscape
3.9 Future market trends
3.10 Porter's analysis
3.11 GAP analysis
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Company market share analysis
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Heart valve devices
- 5.2.1 Surgical heart valves
- 5.2.2 Transcatheter heart valves
5.3 Annuloplasty rings
5.4 Occluders and delivery systems
5.5 Other products

Chapter 6 Market Estimates and Forecast, By Procedure, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Replacement procedures
- 6.2.1 Surgical aortic valve replacement (SAVR)
- 6.2.2 Transcatheter aortic valve replacement (TAVR)
- 6.2.3 Transcatheter mitral valve replacement (TMVR)
- 6.2.4 Other replacement procedures
6.3 Repair procedures
- 6.3.1 Left atrial appendage closure (LAAC)
- 6.3.2 Transcatheter mitral valve repair (TMVr)
- 6.3.3 Transcatheter tricuspid valve repair (TTVr)
- 6.3.4 Valvuloplasty
- 6.3.5 Other repair procedures

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Cardiac catheterization labs
7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE